Challenges of Systemic Therapy for Patients with EGFR-mutated Lung Cancer After Progression on Targeted Therapy
Christi M.J. Steendam, MD, PhD+more
Drs. Christi M.J. Steendam and Sushil K. Badrising review studies comparing outcomes of various treatment regimens in the search for the best-performing approach. Read more
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
Erin JungmeyerDr. Jeffrey D. Bradley presented the data from the phase III study of durvalumab in combination with and following chemoradiotherapy for patients with unresectable, stage III NSCLC during the 2024 European Lung Cancer Congress. Read more
MARIPOSA-2 Post-progression Analysis Favors Amivantamab-Chemotherapy Combination
Erin JungmeyerCompared to chemotherapy alone, the addition of the EGFR-MET bispecific antibody significantly prolonged progression-free survival after subsequent therapy, said Dr. Ryan Gentzler during the European Lung Cancer Congress. Read more
Can Artificial Intelligence Identify Those at High Risk and Shift the Lung Cancer Screening Paradigm?
Erin JungmeyerIn a recent interview, Dr. Lecia V. Sequist, a member of the team behind the Sybil AI algorithm, discusses how technology may soon be able to predict who will develop lung cancer. Read more
US FDA grants accelerated approval of HER2-targeting antibody drug conjugate; China accepts supplemental new drug application for savolitinib. Read more
FLAURA 2 Post-progression Outcomes Demonstrate Consistent Benefit, Favor Combination Arm
Erin JungmeyerDuring the European Lung Cancer Congress, Dr. Natalia Valdiviezo presented the data, which favored frontline osimertinib plus chemotherapy compared to osimertinib alone for patients with EGFR-mutated NSCLC. Read more
Antibody Drug Conjugates: Diamonds in the Rough?
Matthew Lee, MD, MPH+more
Drs. Matthew Lee, Benjamin Levy, and Balazs Halmos say several key issues need to be addressed before this class of agents can achieve wider impact. Read more
The Promise of Artificial Intelligence-Aided Pathology in Thoracic Oncology
Jan von der Thüsen, MD, PhD+more
Profs. Jan von der Thüsen and John Le Quesne say while still in the early phases, AI has the potential to bring accessible and affordable prognosis and response prediction tools to all. Read more
The filing was based on results from a global phase III study designed to compare the ALK inhibitor to crizotinib in the first-line treatment of ALK-positive NSCLC. Read more
IASLC Launches Global Member Survey on Diversity, Equity, and Inclusion
Erin JungmeyerThe association seeks input from members to better understand the current DEI landscape so it can continue to build a diverse international community dedicated to the elimination of thoracic malignancies. Read more